BioSeek to Study Compounds for UCB | GenomeWeb
NEW YORK (GenomeWeb News) - BioSeek said today it has entered into an agreement with the Belgian biopharmaceutical company UCB to evaluate drug compounds.
 
Under the agreement, BioSeek will use its BioMAP systems to support target differentiation, lead development, and drug-candidate selection activities for UCB compounds in several target classes. UCB is focused on developing therapeutics for central nervous system disorders, inflammation, and oncology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.